NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

The Lancet Neurology

Volumn 8, Issue 6, 2009, Pages 519-529

  Sorensen, Per Soelberg ^a   Mellgren, Svein Ivar ^b   Svenningsson, Anders ^c   Elovaara, Irina ^d   Frederiksen, Jette Lautrup ^e   Beiske, Antonie Giaever ^f   Myhr, Kjell Morten ^g   Søgaard, Lise Vejby ^h   Olsen, Inge Christoffer ⁱ   Sandberg Wollheim, Magnhild ^j  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h Mental Health Services CPH   (Denmark)

ⁱ Smerud Medical Research International AS   (Norway)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; METHYLPREDNISOLONE; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BONE DENSITY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENDOCRINE DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE SCLEROSIS; MUSCLE DISEASE; MUSCLE TENDERNESS; NEUROLOGIC DISEASE; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY FAILURE; SKIN MANIFESTATION; SLEEP DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES; CONFIDENCE INTERVALS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PSYCHOMOTOR PERFORMANCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 65549144672     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70085-7     Document Type: Article

References (48)

1. Duquette P., Girard M., Despault L., et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis-clinical-results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. PRISMS (prevention of relapses and disability by interferon β-1a subcutaneously in multiple sclerosis) study group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
3. Delisse B., de Seze J., Mackowiak A., et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 10 (2004) 92
4. Hartung H.-P., Gonsette R., König N., et al., the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
5. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
6. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
7. Beck R.W., Cleary P.A., Trobe J.D., et al., for the Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329 (1993) 1764-1769
8. Zivadinov R., Rudick R.A., De Masi R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
9. Sorensen P.S., Deisenhammer F., Duda P., et al. Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12 (2005) 817-827
10. Giovannoni G., Barbarash O., Casset-Semanaz F., et al. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 15 (2009) 219-228
11. Pozzilli C., Antonini G., Bagnato F., et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249 (2002) 50-56
12. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
13. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
14. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
15. Cohen J.A., Fischer J.S., Bolibrush D.M., et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 54 (2000) 802-806
16. Ross C., Clemmesen K.M., Svenson M., et al., the Danish Multiple Sclerosis Study Group. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48 (2000) 706-712
17. Sorensen P.S., Ross C., Clemmesen K.M., et al., the Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
18. Hesse D., and Sorensen P.S. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 14 (2007) 850-859
19. Zhang Y., Brady M., and Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 20 (2001) 45-57
20. Smith S.M., Jenkinson M., Woolrich M.W., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (2004) 208-219
21. Smith S.M., Zhang Y., Jenkinson M., et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 (2002) 479-489
22. Schumacher G.A., Beebe G., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122 (1965) 552-568
23. Cohen J.A., Cutter G.R., Fischer J.S., et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58 (2001) 961-967
24. Little R., and Rubin D.B. Statistical analysis with missing data. 2nd edn. (2002), John Wiley and Sons, New York
25. Agresti A. Categorical data analysis. 2nd edn. (2002), Wiley Interscience, New Jersey
26. Buttgereit F., Burmester G., and Bijlsma J.W. Which dose regimen for glucocorticoid pulse therapy in patients with severe refractory RA?. Ann Rheum Dis 64 (2005) 171-172
27. Gasperini C., Pozzilli C., Bastianello S., et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 50 (1998) 403-406
28. Sellebjerg F., Jensen C.V., Larsson H.B., and Frederiksen J.L. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler 9 (2003) 102-107
29. Barnes D., Hughes R., Morris R.W., et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349 (1997) 902-906
30. Buttgereit F., and Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 67 (2002) 529-534
31. Ashwell J.D., Lu F.W.M., and Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 18 (2000) 309-345
32. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., and Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42 (1997) 783-793
33. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., and McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34 (1993) 661-669
34. De Bosscher K., Vanden Berghe W., and Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109 (2000) 16-22
35. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., and Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 58 (2001) 91-97
36. Sellebjerg F., Ross C., Koch-Henriksen N., et al. CD26+ CD4+ T cell counts and attack risk in interferon-treated multiple sclerosis. Mult Scler 11 (2005) 641-645
37. Gorelik L., Constant S., and Flavell R.A. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J Exp Med 195 (2002) 1499-1505
38. Link J., He B., Navikas V., et al. Transforming growth factor-β1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 58 (1995) 21-35
39. Sellebjerg F., Christiansen M., Jensen J., and Frederiksen J.L. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 7 (2000) 281-289
40. Fahey A.J., Robins R.A., Kindle K.B., Heery D.M., and Constantinescu C.S. Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. J Leukoc Biol 80 (2006) 133-144
41. Hesse D., Frederiksen J.L., Koch-Henriksen N., et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. Eur J Neurol 16 (2009) 43-47
42. Jacobs L.D., Beck R.W., Simon J.H., et al., the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343 (2000) 898-904
43. Beck R.W., and the Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis: a need to change treatment practices. Neurology 42 (1992) 1133-1135
44. Goodkin D.E., Kinkel R.P., Weinstock G.B., et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51 (1998) 239-245
45. Rudick R.A., Stuart W.H., Calabresi P.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 (2006) 911-923
46. Cohen J., Calabresi P., Chakraborty S., et al. Avonex Combination Trial in relapsing-remitting MS: rationale, design and baseline data. Mult Scler 14 (2008) 370-382
47. Cohen J.A., Imrey P.B., Calabresi P.A., et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72 (2009) 535-541
48. Ravnborg M, Sorensen PS, Andersson ML, et al. A multi-centre, double blind, randomized, placebo controlled, parallel group trial investigating methylprednisolone (MP) as add-on to interferon beta-1a for the treatment of relapsing-remitting multiple sclerosis. Presented at the American Academy of Neurology 2009 Annual Meeting. Seattle, WA, USA. April, 2009. Abstract LB3.002.